Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent adult Hodgkin lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, stage III multiple myeloma, refractory multiple myeloma, Waldenström macroglobulinemia, recurrent adult Burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, cutaneous B-cell non-Hodgkin lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent adult grade III lymphomatoid granulomatosis
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed diagnosis of 1 of the following:
- Multiple myeloma
- Non-Hodgkin's lymphoma
- Hodgkin's lymphoma
- Relapsed or refractory disease
Measurable disease, as defined according to diagnosis as follows:
Multiple myeloma, meeting 1 of the following criteria:
- Serum monoclonal protein ≥ 1.0 g/dL
- Urine monoclonal protein ≥ 200 mg by 24-hour electrophoresis
- Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
- Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)
Lymphoma, meeting 1 of the following criteria:
Measurable disease by CT scan or MRI or PET/CT scan, defined as ≥ 1 lesion that has a single diameter of ≥ 2 cm OR tumor cells in the blood ≥ 5 x10^9/L
- Skin lesions can be used if the area is ≥ 2 cm in ≥ 1 diameter and photographed with a ruler
Lymphoplasmacytic lymphoma without measurable lymphadenopathy, meeting both of the following criteria:
- Bone marrow lymphoplasmacytosis with > 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy
- Quantitative IgM monoclonal protein > 1,000 mg/dL
- Not a candidate for known standard potentially curative therapy
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 9 g/dL
- Platelet count ≥ 75,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal
- AST ≤ 3 times ULN (5 times ULN if liver involvement)
- Creatinine ≤ 2.5 times ULN
- INR < 1.5 or activated PTT < 1.5 times ULN (no concurrent anticoagulants)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for at least 2 weeks after completion of study treatment
- No uncontrolled infection
- No NYHA class III-IV congestive heart failure
- No unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months)
- No myocardial infarction within the past 6 months
- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg, despite optimal medical management
- No known HIV positivity
- No other active malignancy requiring treatment
- No inability to swallow
- No gastrointestinal (GI) function impairment or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or small bowel resection) or preclude use of oral medications
- No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months
- No pulmonary hemorrhage or bleeding event ≥ grade 3 within the past 4 weeks
- No severe or uncontrolled medical conditions or other conditions that would preclude study compliance
- No liver disease, such as cirrhosis, chronic hepatitis or chronic persistent hepatitis, or uncontrolled infections
- No serious nonhealing wound, ulcer, or bone fracture
- No evidence or history of serious bleeding diathesis or coagulopathy, such as hemophilia or von Willebrand's disease
- No significant traumatic injury within the past 4 weeks
- No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus)
PRIOR CONCURRENT THERAPY:
- More than 3 weeks since prior myelosuppressive chemotherapy or biological therapy and recovered
More than 4 weeks since prior major surgery or open biopsy
- Lymph node biopsy within past 4 weeks allowed
- Prior everolimus allowed
No concurrent immunosuppressant therapy
- Concurrent stable chronic doses of steroids (≤ 20 mg of prednisone per day) for disorders other than lymphoma (i.e., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, asthma) or for pruritus or fever associated with lymphoma allowed
- Concurrent corticosteroids at the lowest possible dose necessary to control symptoms in patients with CNS lymphoma allowed
- No concurrent CYP450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)
- No other concurrent immunotherapy, radiotherapy, or chemotherapy
- No concurrent chronic oxygen therapy
- No concurrent warfarin or heparin
- No other concurrent investigational therapy
Sites / Locations
- Holden Comprehensive Cancer Center at University of Iowa
- Mayo Clinic Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Multiple Myeloma
Lymphoma
Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;